if your desired mg/hr is:
If your desired mg/hr is: | at a 4 mg/mL concentration (1,000 mg in 250 mL), administer at: | at a 2 mg/mL concentration (1,000 mg in 500 mL), administer at: | at a 1 mg/mL concentration (1,000 mg in 1,000 mL), administer at: |
---|---|---|---|
50 mg/hr | 13 mL/hr | 25 mL/hr | 50 mL/hr |
100 mg/hr | 25 mL/hr | 50 mL/hr | 100 mL/hr |
150 mg/hr | 38 mL/hr | 75 mL/hr | 150 mL/hr |
200 mg/hr | 50 mL/hr | 100 mL/hr | 200 mL/hr |
250 mg/hr | 63 mL/hr | 125 mL/hr | 250 mL/hr |
300 mg/hr | 75 mL/hr | 150 mL/hr | 300 mL/hr |
350 mg/hr | 88 mL/hr | 175 mL/hr | 350 mL/hr |
400 mg/hr | 100 mL/hr | 200 mL/hr | 400 mL/hr |
900 mg/hr* | 225 mL/hr | 450 mL/hr | 900 mL/hr |
Dilute GAZYVA with 0.9% sodium chloride to achieve a final concentration ranging from 0.4 mg/mL to 4 mg/mL.
Do not use other diluents such as dextrose (5%).
Interested in more information about GAZYVA?
GAZYVA full Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2022.
GAZYVA full Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2022.
Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402.
Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402.
Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12(10):2031-2042.
Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12(10):2031-2042.
Klein C, Lammens A, Schäfer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. mAbs. 2013;5(1):22-33.
Klein C, Lammens A, Schäfer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. mAbs. 2013;5(1):22-33.
Honeychurch J, Alduaij W, Azizyan M, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012;119(15):3523-3533.
Honeychurch J, Alduaij W, Azizyan M, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012;119(15):3523-3533.
VENCLEXTA® (venetoclax tablets) Prescribing Information. North Chicago, IL: AbbVie Inc; 2022.
VENCLEXTA® (venetoclax tablets) Prescribing Information. North Chicago, IL: AbbVie Inc; 2022.
CALQUENCE® (acalabrutinib) Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.
CALQUENCE® (acalabrutinib) Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.
IMBRUVICA® (ibrutinib) Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; 2022.
IMBRUVICA® (ibrutinib) Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; 2022.
Data on file. Genentech, Inc.
Data on file. Genentech, Inc.
Seymour JF, Marcus R, Davies A, et al. Haematologica. 2019;104(6):1202-1208.
Seymour JF, Marcus R, Davies A, et al. Haematologica. 2019;104(6):1202-1208.
Casulo C, Byrtek M, Dawson KL, et al. J Clin Oncol. 2015;33(23):2516-2522.
Casulo C, Byrtek M, Dawson KL, et al. J Clin Oncol. 2015;33(23):2516-2522.
Canales M, Buchholz T, Izutsu K, et al. Obinutuzumab short duration infusion in previously untreated advanced follicular lymphoma: results from the end of induction analysis of the phase IV GAZELLE study. Presented at ASCO 2021.
Canales M, Buchholz T, Izutsu K, et al. Obinutuzumab short duration infusion in previously untreated advanced follicular lymphoma: results from the end of induction analysis of the phase IV GAZELLE study. Presented at ASCO 2021.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.